A Phase 3 interventional study of Atezolizumab and Lurbinectedin in Small-Cell Lung Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 93 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing PM 01183 in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 3 of them phase 3. PM 01183 · Small Cell Lung Carcinoma.
Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 5 in phase 3, reaches primary completion later than 0 of the 10 other live ones, and was the 6th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →9 of the 16 studies testing PM 01183 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Misty Shields · Sites in United States
Ages 18+
Jazz Pharmaceuticals · Sites in United States
Ages 18+
Gilead Sciences · Sites in United States, Argentina, Australia and 20 more countries
Ages 18+
Luye Pharma Group Ltd. · Sites in China
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
PM 01183: first FDA approval 2020 (ZEPZELCA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5
First in 2013; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 660 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 69 across the 16 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche: 1 open now, 2 under way, 1 of them phase 3. Of 14 finished, 6 (43%) have results posted.
Among the 16 studies in Small Cell Lung Carcinoma by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2021, is one of 5 in phase 3, and was the 14th registered.
Hoffmann-La Roche’s Small Cell Lung Carcinoma studies by the year they started, since 2007.
4 of the studies testing PM 01183 in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06501976Cancer Institute and Hospital, Chinese Academy of Medical SciencesAn Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment | 2026-12 |
| NCT05578326UNC Lineberger Comprehensive Cancer CenterStudy of Trilaciclib and Lurbinectidin | 2026-12-25 |
| NCT07640932Yonsei UniversityLurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer | 2027-04 |
| NCT06228066National Cancer Institute (NCI)Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, from their registry updates:
Among Hoffmann-La Roche’s 16 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab alone administered as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and atezolizumab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab induction treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
Inclusion Criteria for the Induction Phase:
Exclusion Criteria for the Induction Phase:
Inclusion Criteria for the Maintenance Phase:
Exclusion Criteria for the Maintenance Phase:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles. Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle.
Drug: Atezolizumab · Drug: Lurbinectedin · Drug: Carboplatin · Drug: Etoposide
Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles. Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle.
Drug: Atezolizumab · Drug: Carboplatin · Drug: Etoposide
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle for 4 cycles in the induction phase. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle in the maintenance phase.
Also known as: Tecentriq, RO5541267
Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 of each 21-day cycle in the maintenance phase.
Also known as: PM01183/JZP712
Carboplatin will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Etoposide will be administered according to the standard of care treatment for 4 cycles in the induction phase.
Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)
PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm).
Time frame: Up to 26 months
Randomized Phase: Overall Survival (OS)
OS was defined as the time from randomization to the date of death from any cause.
Time frame: Up to 26 months
Randomized Phase: Investigator-assessed PFS
PFS was defined as the time from randomization to the date of first documented PD as assessed by investigator according to RECIST v1.1 or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 26 months
Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF
ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the IRF using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Percentages have been rounded off.
Time frame: Up to 26 months
Randomized Phase: Confirmed ORR as Determined by the Investigator
ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.
Time frame: Up to 26 months
Randomized Phase: Duration of Response (DOR) as Determined by the IRF
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by IRF assessment using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 26 months
Randomized Phase: DOR as Determined by the Investigator
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by investigator using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 26 months
Randomized Phase: Percentage of Participants With PFS as Determined by the IRF at 6 Months and 12 Months
PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the IRF according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.
Time frame: Months 6 and 12
Randomized Phase: Percentage of Participants With PFS Determined by Investigator at 6 Months and 12 Months
PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.
Time frame: Months 6 and 12
Randomized Phase: Percentage of Participants With OS at 12 Months and 24 Months
OS rate at 12 months and 24 months was defined as the percentage of participants who had not experienced death from any cause at 12 months and 24 months after randomization. Percentages have been rounded off.
Time frame: Months 12 and 24
Randomized Phase: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI)
An AE =any unfavorable \& unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of a pharmaceutical product, whether considered related to the pharmaceutical product. SAE=any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. AESI= drug induced liver injury, suspected transmission of infectious agent via study treatment, hepatitis, systemic lupus erythematosus, hypersensitivity, etc. AESIs may include events not specified in the protocol.
Time frame: Up to 26 months
Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed at least one positive post-baseline ADA result during the randomized phase, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.
Time frame: Up to 26 months
Randomized Phase: Time to Confirmed Deterioration (TTCD) in Physical Functioning (PF) and Global Health Status (GHS) as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQC30)
EORTC QLQ-C30=30 questions assessing 5 aspects of participant functioning(physical,emotional,role,cognitive \&social),3 symptom scales,GHS/QoL \& 6 single items.PF scale=5 questions about participants PF \& daily activities(strenuous activities,long walks,short walks,bed/chair rest \& needing help with eating,dressing,washing themselves/using the toilet).PF scale scored on 4-point scale(1=Not at All-4=Very Much).GHS/QoL scored on 7-point scale(1=Very Poor- 7=Excellent).Scores were linearly transformed to a range of 0-100,higher scores=higher response level \& better QoL.TTCD for PF \& GHS/QoL=time from the date of randomization until first confirmed clinically meaningful deterioration,which is decrease from baseline in PF/GHS score that must be held for at least 2 consecutive assessments/initial decrease above baseline followed by death attributable to cancer progression within 6 weeks of the last deteriorated assessment.Score change≥10-point change in subscale score,considered meaningful.
Time frame: Up to 26 months
A total of 660 participants with ES SCLC took part in the study across 96 investigative sites in 13 countries.
| Milestone | Atezolizumab + Carboplatin + Etoposide | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|---|
| Started | 660 | 0 | 0 |
| Enrolled safety analysis set (sas) | 653 | 0 | 0 |
| Completed | 571 | 0 | 0 |
| Not completed | 89 | 0 | 0 |
| Withdrew: Death | 37 | 0 | 0 |
| Withdrew: Adverse event | 21 | 0 | 0 |
| Withdrew: Progressive disease | 10 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 0 | 0 |
| Withdrew: Symptomatic deterioration | 7 | 0 | 0 |
| Withdrew: Physician decision | 3 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 0 | 0 |
| Milestone | Atezolizumab + Carboplatin + Etoposide | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|---|
| Started | 0 | 241 | 242 |
| Sas | 0 | 240 | 242 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 241 | 242 |
| Withdrew: Death | 0 | 135 | 112 |
| Withdrew: Progressive disease | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Ongoing in study | 0 | 102 | 126 |
PFS was defined as the time from randomization to the date of first documented PD as determined by the IRF according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimetres (mm).
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS) | 2.14 ± 1.64 | 5.36 ± 4.24 |
OS was defined as the time from randomization to the date of death from any cause.
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Overall Survival (OS) | 10.64 ± 9.49 | 13.24 ± 11.89 |
PFS was defined as the time from randomization to the date of first documented PD as assessed by investigator according to RECIST v1.1 or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Investigator-assessed PFS | 2.73 ± 2.53 | 5.36 ± 4.30 |
ORR was defined as the percentage of participants with an objective tumor response of complete response (CR) or partial response (PR) as determined by the IRF using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. Percentages have been rounded off.
| percentage of participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Confirmed Objective Response Rate (ORR) as Determined by the IRF | 10.4 ± 6.40 | 19.4 ± 13.85 |
ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.
| percentage of participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Confirmed ORR as Determined by the Investigator | 13.2 ± 8.86 | 17.1 ± 12.19 |
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by IRF assessment using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Duration of Response (DOR) as Determined by the IRF | 5.62 (4.17 to NA) | 9.00 (5.52 to NA) |
DOR was calculated for participants who had a best confirmed OR of CR/PR. DOR= time from first occurrence of a documented OR until the time of documented PD as determined by investigator using RECIST v1.1 or death from any cause, whichever occurs first. CR=disappearance of all target and non-target lesions or any pathological lymph nodes (whether target or non-target) having a reduction in short axis to \<10 mm. PR= at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: DOR as Determined by the Investigator | 11.93 (8.38 to NA) | 5.75 (4.17 to 11.10) |
PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the IRF according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.
| percentage of participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| 6 Months | 18.66 ± 13.45 | 41.22 ± 34.58 |
| 12 Months | 12.03 ± 7.27 | 20.54 ± 14.37 |
PFS rate at 6 months and 12 months was defined as the percentage of participants who had not experienced PD as determined by the investigator according to RECIST v1.1 or death from any cause at 6 months and 12 months after randomization. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Percentages have been rounded off.
| percentage of participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| 6 Months | 22.56 ± 17.12 | 46.21 ± 39.60 |
| 12 Months | 12.80 ± 8.07 | 20.32 ± 14.33 |
OS rate at 12 months and 24 months was defined as the percentage of participants who had not experienced death from any cause at 12 months and 24 months after randomization. Percentages have been rounded off.
Results for this outcome have not been posted.
An AE =any unfavorable \& unintended sign (including abnormal laboratory values/abnormal clinical test results), symptoms/disease temporally associated with the use of a pharmaceutical product, whether considered related to the pharmaceutical product. SAE=any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. AESI= drug induced liver injury, suspected transmission of infectious agent via study treatment, hepatitis, systemic lupus erythematosus, hypersensitivity, etc. AESIs may include events not specified in the protocol.
| Participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| AEs | 194 | 235 |
| SAEs | 41 | 75 |
| AESIs for Atezolizumab | 54 | 76 |
| AESIs for Lurbinectedin | 62 | 93 |
For determining post-baseline incidence, participants were considered to be ADA-positive if they were ADA-negative or had missing data at baseline but developed at least one positive post-baseline ADA result during the randomized phase, or if they were ADA-positive at baseline and the titer of 1 or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the baseline titer result.
| Participants | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| Randomized Phase: Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab | 20 | 19 |
EORTC QLQ-C30=30 questions assessing 5 aspects of participant functioning(physical,emotional,role,cognitive \&social),3 symptom scales,GHS/QoL \& 6 single items.PF scale=5 questions about participants PF \& daily activities(strenuous activities,long walks,short walks,bed/chair rest \& needing help with eating,dressing,washing themselves/using the toilet).PF scale scored on 4-point scale(1=Not at All-4=Very Much).GHS/QoL scored on 7-point scale(1=Very Poor- 7=Excellent).Scores were linearly transformed to a range of 0-100,higher scores=higher response level \& better QoL.TTCD for PF \& GHS/QoL=time from the date of randomization until first confirmed clinically meaningful deterioration,which is decrease from baseline in PF/GHS score that must be held for at least 2 consecutive assessments/initial decrease above baseline followed by death attributable to cancer progression within 6 weeks of the last deteriorated assessment.Score change≥10-point change in subscale score,considered meaningful.
| months | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|
| TTCD for PF | NA (NA to NA) | 15.9 (11.0 to NA) |
| TTCD for GHS/QoL | 12.9 (11.6 to NA) | 10.8 (7.6 to NA) |
Collected over Enrollment Phase: Up to 6 months Randomization Phase: up to 26 months Study is ongoing & data up to primary clinical cut-off date is reported. Final data to be reported 1 year after study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Atezolizumab + Carboplatin + Etoposide | 54/660 (8.2%) | 181/653 (27.7%) | 526/653 (80.6%) |
| Atezolizumab | 135/241 (56%) | 41/240 (17.1%) | 127/240 (52.9%) |
| Atezolizumab+ Lurbinectedin | 113/242 (46.7%) | 75/242 (31%) | 213/242 (88%) |
| Event | Atezolizumab + Carboplatin + Etoposide | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 25/653 | 0/240 | 2/242 |
| PneumoniaInfections and infestations | 22/653 | 6/240 | 6/242 |
| Febrile neutropeniaBlood and lymphatic system disorders | 22/653 | 0/240 | 4/242 |
| Respiratory tract infectionInfections and infestations | 3/653 | 1/240 | 5/242 |
| Platelet count decreasedInvestigations | 4/653 | 0/240 | 5/242 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/653 | 4/240 | 5/242 |
| HyponatraemiaMetabolism and nutrition disorders | 12/653 | 3/240 | 2/242 |
| SepsisInfections and infestations | 11/653 | 1/240 | 1/242 |
| InfectionInfections and infestations | 0/653 | 0/240 | 3/242 |
| Myocardial infarctionCardiac disorders | 2/653 | 0/240 | 3/242 |
| Event | Atezolizumab + Carboplatin + Etoposide | Atezolizumab | Atezolizumab+ Lurbinectedin |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 268/653 | 16/240 | 75/242 |
| NauseaGastrointestinal disorders | 114/653 | 9/240 | 86/242 |
| FatigueGeneral disorders | 76/653 | 19/240 | 48/242 |
| Decreased appetiteMetabolism and nutrition disorders | 67/653 | 16/240 | 41/242 |
| NeutropeniaBlood and lymphatic system disorders | 110/653 | 4/240 | 26/242 |
| AlopeciaSkin and subcutaneous tissue disorders | 108/653 | 2/240 | 1/242 |
| Neutrophil count decreasedInvestigations | 102/653 | 3/240 | 31/242 |
| Platelet count decreasedInvestigations | 49/653 | 7/240 | 35/242 |
| DiarrhoeaGastrointestinal disorders | 55/653 | 18/240 | 34/242 |
| ConstipationGastrointestinal disorders | 90/653 | 13/240 | 27/242 |
Full Analysis Set (FAS) included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received. Analysis was performed on the randomized treatment arms.
| Age, Continuous(years) | Atezolizumab | Atezolizumab+ Lurbinectedin | Total |
|---|---|---|---|
| Mean | 66.0 ± 8.0 | 65.1 ± 7.6 | 65.5 ± 7.8 |
| Sex: Female, Male(Participants) | Atezolizumab | Atezolizumab+ Lurbinectedin | Total |
|---|---|---|---|
| Female | 90 | 91 | 181 |
| Male | 151 | 151 | 302 |
| Ethnicity (NIH/OMB)(Participants) | Atezolizumab | Atezolizumab+ Lurbinectedin | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 16 | 32 |
| Not Hispanic or Latino | 210 | 206 | 416 |
| Unknown or Not Reported | 15 | 20 | 35 |
| Race (NIH/OMB)(Participants) | Atezolizumab | Atezolizumab+ Lurbinectedin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 31 | 31 | 62 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 199 | 195 | 394 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 10 | 12 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Nov 2021 to primary completion in Jul 2024, 32 months.
Results were first posted in Dec 2025, 1 year 5 months after primary completion.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 32 months is close to that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PM 01183